At this time, Bosulif (bosutinib) tablets are available in brand-name form only. However, after the first patent for the drug expires in March 2018, companies may be allowed to make a generic version of this drug. Although bosutinib is often referred to as the "generic name" for Bosulif, it is simply the active ingredient in this medicine and is not a generic version of it.
Bosulif® (bosutinib) is a prescription medication used in the treatment of a certain type of leukemia known as chronic myelogenous leukemia. It is used after other treatments have failed or were not tolerated.
Bosulif is made by Pfizer Labs. It is currently protected from generic competition by patents that have yet to expire.
The first patent for Bosulif is set to expire in March 2018. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to delay or shorten this exclusivity period. This could include things such as lawsuits or other patents for new Bosulif uses. Once Bosulif goes off-patent, there may be several companies that manufacture a generic Bosulif drug.
No, bosutinib is the active ingredient in Bosulif, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent, and another company besides the original manufacturer must make the product.